A University of Kentucky Martin-Gatton College of Agriculture, Food and Environment researcher is leading a new project that ...

Wave Life Sciences recently released its latest 10-Q report. The company is a clinical-stage biotechnology firm based in ...

Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 ...

CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference ...

AviadoBio will combine its proprietary vMiX™ RNAi platform with Apertura’s novel human TfR1 capsid (TfR1 CapX™) to enable one ...

The trial will assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of BW-50218 in participants.

Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follo ...

Aedes aegypti, commonly known as the yellow fever mosquito, is a highly adapted, invasive mosquito species recognized as a ...

University of Kentucky researchers are working on a new way of eliminating an invasive insect species that’s been a blight to ...

By tracking immune RNA fragments, researchers identified new mosquito viruses, and showed how some evade detection, offering ...